| Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] |
| |
|
As of June 30, 2023 |
|
| |
|
As Reported |
|
|
Adjustment |
|
|
As Restated |
|
| Assets |
|
|
|
|
|
|
|
|
|
|
|
|
| Prepaid research and development costs |
|
$ |
5,532,410 |
|
|
$ |
(2,016,947 |
) |
|
$ |
3,515,463 |
|
| Total current assets |
|
$ |
34,684,629 |
|
|
$ |
(2,016,947 |
) |
|
$ |
32,667,682 |
|
| Total assets |
|
$ |
62,221,029 |
|
|
$ |
(2,016,947 |
) |
|
$ |
60,204,082 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Liabilities and Stockholders' Equity |
|
|
|
|
|
|
|
|
|
|
|
|
| Accounts payable |
|
$ |
18,118,594 |
|
|
$ |
(2,174,590 |
) |
|
$ |
15,944,004 |
|
| Accrued research and development costs |
|
$ |
1,112,788 |
|
|
$ |
924,273 |
|
|
$ |
2,037,061 |
|
| Total current liabilities |
|
$ |
27,686,180 |
|
|
$ |
(1,250,317 |
) |
|
$ |
26,435,863 |
|
| Total liabilities |
|
$ |
40,808,163 |
|
|
$ |
(1,250,317 |
) |
|
$ |
39,557,846 |
|
| Accumulated deficit |
|
$ |
(247,869,464 |
) |
|
$ |
(766,630 |
) |
|
$ |
(248,636,094 |
) |
| Total stockholders' equity |
|
$ |
21,412,866 |
|
|
$ |
(766,630 |
) |
|
$ |
20,646,236 |
|
| Total liabilities and stockholders' equity |
|
$ |
62,221,029 |
|
|
$ |
(2,016,947 |
) |
|
$ |
60,204,082 |
|
| |
|
Three Months Ended June 30, 2023 |
|
| |
|
As Reported |
|
|
Adjustment |
|
|
As Restated |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Research and development |
|
$ |
2,925,171 |
|
|
$ |
5,862,465 |
|
|
$ |
8,787,636 |
|
| Total operating expenses |
|
$ |
13,828,087 |
|
|
$ |
5,862,465 |
|
|
$ |
19,690,552 |
|
| Operating loss |
|
$ |
(7,873,846 |
) |
|
$ |
(5,862,465 |
) |
|
$ |
(13,736,311 |
) |
| Loss before income taxes |
|
$ |
(6,602,630 |
) |
|
$ |
(5,862,465 |
) |
|
$ |
(12,465,095 |
) |
| Net loss |
|
$ |
(6,660,181 |
) |
|
$ |
(5,862,465 |
) |
|
$ |
(12,522,646 |
) |
| Net loss per basic and diluted common shares outstanding |
|
$ |
(0.08 |
) |
|
$ |
(0.06 |
) |
|
$ |
(0.14 |
) |
| |
|
Nine Months Ended June 30, 2023 |
|
| |
|
As Reported |
|
|
Adjustment |
|
|
As Restated |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Research and development |
|
$ |
44,534,153 |
|
|
$ |
2,725,311 |
|
|
$ |
47,259,464 |
|
| Total operating expenses |
|
$ |
93,629,142 |
|
|
$ |
2,725,311 |
|
|
$ |
96,354,453 |
|
| Operating loss |
|
$ |
(82,880,771 |
) |
|
$ |
(2,725,311 |
) |
|
$ |
(85,606,082 |
) |
| Loss before income taxes |
|
$ |
(82,372,552 |
) |
|
$ |
(2,725,311 |
) |
|
$ |
(85,097,863 |
) |
| Net loss |
|
$ |
(82,295,266 |
) |
|
$ |
(2,725,311 |
) |
|
$ |
(85,020,577 |
) |
| Net loss per basic and diluted common shares outstanding |
|
$ |
(0.99 |
) |
|
$ |
(0.03 |
) |
|
$ |
(1.02 |
) |
| |
|
Nine Months Ended June 30, 2023 |
|
| |
|
As Reported |
|
|
Adjustment |
|
|
As Restated |
|
| OPERATING ACTIVITIES |
|
|
|
|
|
|
|
|
|
|
|
|
| Net loss |
|
$ |
(82,295,266 |
) |
|
$ |
(2,725,311 |
) |
|
$ |
(85,020,577 |
) |
| Decrease in prepaid expenses and other assets |
|
$ |
5,780,913 |
|
|
$ |
1,249,380 |
|
|
$ |
7,030,293 |
|
| Decrease in accounts payable |
|
$ |
(3,884,800 |
) |
|
$ |
(2,174,590 |
) |
|
$ |
(6,059,390 |
) |
| Decrease in accrued expenses and other current liabilities |
|
$ |
(10,358,135 |
) |
|
$ |
3,650,521 |
|
|
$ |
(6,707,614 |
) |
|